BR112018013807A2 - ?anticorpo anti-myl9? - Google Patents

?anticorpo anti-myl9?

Info

Publication number
BR112018013807A2
BR112018013807A2 BR112018013807-0A BR112018013807A BR112018013807A2 BR 112018013807 A2 BR112018013807 A2 BR 112018013807A2 BR 112018013807 A BR112018013807 A BR 112018013807A BR 112018013807 A2 BR112018013807 A2 BR 112018013807A2
Authority
BR
Brazil
Prior art keywords
myl9
human
antibody
mouse
monoclonal antibody
Prior art date
Application number
BR112018013807-0A
Other languages
English (en)
Japanese (ja)
Inventor
Nakayama Toshinori
Kimura Motoko
HAYASHIZAKI Koji
Hirayama Toshifumi
KAKUTA Jungo
Sakamoto Yoshimasa
Gejima Ryu
Tokita Daisuke
Muramoto Kenzo
Imai Toshio
Original Assignee
National University Corporation Chiba University
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Chiba University, Eisai R&D Management Co., Ltd. filed Critical National University Corporation Chiba University
Publication of BR112018013807A2 publication Critical patent/BR112018013807A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção proporciona um anticorpo anti-myl9 ou um fragmento de ligação a myl9 do mesmo que se liga a myl9 e pode inibir a interação entre myl9 e cd69 em seres humanos, bem como uma composição farmacêutica compreendendo o mesmo. um anticorpo monoclonal de camundongo anti-myl9 humano/de camundongo que tem afinidade de ligação em relação a myl9 foi obtido e a sequência para a região determinante de complementaridade (cdr) do referido anticorpo monoclonal de camundongo anti-myl9 humano/de camundongo foi identificada. assim, um anticorpo humanizado compreendendo a sequência de cdr do referido anticorpo monoclonal de camundongo anti-myl9 humano/de camundongo na região variável das cadeias pesada e leve foi produzido.
BR112018013807-0A 2016-01-12 2017-01-11 ?anticorpo anti-myl9? BR112018013807A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016003429 2016-01-12
JP2016-003429 2016-01-12
PCT/JP2017/000605 WO2017122666A1 (ja) 2016-01-12 2017-01-11 抗Ｍｙｌ９抗体

Publications (1)

Publication Number Publication Date
BR112018013807A2 true BR112018013807A2 (pt) 2018-12-11

Family

ID=59311587

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013807-0A BR112018013807A2 (pt) 2016-01-12 2017-01-11 ?anticorpo anti-myl9?

Country Status (14)

Country Link
US (1) US10513561B2 (pt)
EP (1) EP3404040B1 (pt)
JP (1) JP6872756B2 (pt)
KR (1) KR20180098570A (pt)
CN (1) CN108431037B (pt)
AU (1) AU2017207082B2 (pt)
BR (1) BR112018013807A2 (pt)
CA (1) CA3008786A1 (pt)
ES (1) ES2913162T3 (pt)
IL (1) IL260083B2 (pt)
MA (1) MA43869A (pt)
MX (1) MX2018008358A (pt)
RU (1) RU2741802C2 (pt)
WO (1) WO2017122666A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007108A1 (en) * 2019-07-05 2021-01-14 Icahn School Of Medicine At Mount Sinai Method for preventing hair loss
WO2024080377A1 (ja) * 2022-10-14 2024-04-18 国立大学法人千葉大学 肺高血圧症の検出方法及び肺高血圧症の治療薬若しくは予防薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502115A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 小細胞肺癌の診断方法
AU2006278282A1 (en) 2005-08-09 2007-02-15 University Of Virginia Patent Foundation Methods and compositions for inhibition of vascular permeablility
JP4777785B2 (ja) * 2006-01-31 2011-09-21 独立行政法人科学技術振興機構 ケモカインレセプターｃｃｒ５のｎ末端領域に対する抗体酵素
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
ES2829423T3 (es) * 2009-04-20 2021-05-31 Kyowa Kirin Co Ltd Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
EP2421899B1 (en) * 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
KR101787118B1 (ko) * 2009-08-07 2017-10-18 교와 핫꼬 기린 가부시키가이샤 항아밀로이드β 올리고머 인간화 항체
CA2928851A1 (en) * 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
CA2890658A1 (en) * 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
US9758574B2 (en) 2013-05-30 2017-09-12 National University Corporation Chiba University Inflammatory disease treatment composition including anti-myosin regulatory light-chain polypeptide antibody
JP6563389B2 (ja) 2013-06-27 2019-08-21 モナッシュ ユニバーシティ Ｉｌ−２１結合タンパク質及びその使用
ES2818800T3 (es) 2014-06-11 2021-04-14 Idac Theranostics Inc Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario

Also Published As

Publication number Publication date
CN108431037B (zh) 2021-12-17
AU2017207082B2 (en) 2023-07-13
RU2018124601A3 (pt) 2020-04-30
EP3404040A1 (en) 2018-11-21
JP6872756B2 (ja) 2021-05-19
MA43869A (fr) 2018-11-21
US10513561B2 (en) 2019-12-24
IL260083B2 (en) 2023-09-01
WO2017122666A1 (ja) 2017-07-20
CA3008786A1 (en) 2017-07-20
IL260083A (en) 2018-07-31
RU2018124601A (ru) 2020-02-14
EP3404040A4 (en) 2019-08-07
EP3404040B1 (en) 2022-03-02
US20190002588A1 (en) 2019-01-03
IL260083B1 (en) 2023-05-01
AU2017207082A1 (en) 2018-07-05
JPWO2017122666A1 (ja) 2018-11-01
MX2018008358A (es) 2018-09-21
ES2913162T3 (es) 2022-05-31
RU2741802C2 (ru) 2021-01-28
KR20180098570A (ko) 2018-09-04
CN108431037A (zh) 2018-08-21

Similar Documents

Publication Publication Date Title
FR23C1012I1 (fr) Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CL2019003796A1 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas.
CR20180318A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
BR112018001374A2 (pt) construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
BR112018000475A2 (pt) construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
BR112018001638A8 (pt) construtos de anticorpo biespecífico que se ligam à mesotelina e cd3
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
BR112017014805A2 (pt) anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123
BR112015021979A2 (pt) Anticorpos humanos para grem1
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
CL2015002756A1 (es) Moléculas fc biespecíficas
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
BR112016021083A2 (pt) Conjugados anticorpo-fynomer
BR112017020413A2 (pt) ?anticorpo anti-notch4 humano?
BR112017022326A2 (pt) construções de anticorpo biespecífico para cdh3 e cd3
BR112016025056A2 (pt) uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
BR112017025332A2 (pt) anticorpos específicos de receptor de célula t
BR112019020448A2 (pt) anticorpo biespecífico heterodimérico similar à estrutura do anticorpo anti-pd-l1/anti-pd-1 natural e preparação do mesmo

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements